|
1.
|
Ribas A, Butterfield LH, Glaspy JA and
Economou JS: Current developments in cancer vaccines and cellular
immunotherapy. J Clin Oncol. 21:2415–2432. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Rosenberg SA, Yang JC and Restifo NP:
Cancer immunotherapy: moving beyond current vaccines. Nat Med.
10:909–915. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Liu Z, Kim JH, Falo LD II and You Z: Tumor
regulatory T cells potently abrogate antitumor immunity. J Immunol.
182:6160–6167. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Bluestone JA and Abbas AK: Natural versus
adaptive regulatory T cells. Nat Rev Immunol. 3:253–257. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Ling KL, Pratap SE, Bates GJ, et al:
Increased frequency of regulatory T cells in peripheral blood and
tumour infiltrating lymphocytes in colorectal cancer patients.
Cancer Immun. 7:72007.PubMed/NCBI
|
|
6.
|
Wolf AM, Wolf D, Steurer M, Gastl G,
Gunsilius E and Grubeck-Loebenstein B: Increase of regulatory T
cells in the peripheral blood of cancer patients. Clin Cancer Res.
9:606–612. 2003.PubMed/NCBI
|
|
7.
|
Sasada T, Kimura M, Yoshida Y, Kanai M and
Takabayashi A: CD4+CD25+ regulatory T cells
in patients with gastrointestinal malignancies: possible
involvement of regulatory T cells in disease progression. Cancer.
98:1089–1099. 2003.
|
|
8.
|
Kono K, Kawaida H, Takahashi A, et al:
CD4(+)CD25 high regulatory T cells increase with tumor stage in
patients with gastric and esophageal cancers. Cancer Immunol
Immunother. 55:1064–1071. 2006.
|
|
9.
|
Gray CP, Arosio P and Hersey P:
Association of increased levels of heavy-chain ferritin with
increased CD4+ CD25+ regulatory T-cell levels
in patients with melanoma. Clin Cancer Res. 9:2551–2559.
2003.PubMed/NCBI
|
|
10.
|
Liyanage UK, Moore TT, Joo HG, et al:
Prevalence of regulatory T cells is increased in peripheral blood
and tumor microenvironment of patients with pancreas or breast
adenocarcinoma. J Immunol. 169:2756–2761. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Schaefer C, Kim GG, Albers A, Hoermann K,
Myers EN and Whiteside TL: Characteristics of
CD4+CD25+ regulatory T cells in the
peripheral circulation of patients with head and neck cancer. Br J
Cancer. 92:913–920. 2005.
|
|
12.
|
Curiel TJ, Coukos G, Zou L, et al:
Specific recruitment of regulatory T cells in ovarian carcinoma
fosters immune privilege and predicts reduced survival. Nat Med.
10:942–949. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Nicholl M, Lodge A, Brown I, Sugg SL and
Shilyansky J: Restored immune response to an MHC-II-restricted
antigen in tumor-bearing hosts after elimination of regulatory T
cells. J Pediatr Surg. 39:941–946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Zou W: Regulatory T cells, tumour immunity
and immunotherapy. Nat Rev Immunol. 6:295–307. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Barnett B, Kryczek I, Cheng P, Zou W and
Curiel TJ: Regulatory T cells in ovarian cancer: biology and
therapeutic potential. Am J Reprod Immunol. 54:369–377. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Dannull J, Su Z, Rizzieri D, et al:
Enhancement of vaccine-mediated antitumor immunity in cancer
patients after depletion of regulatory T cells. J Clin Invest.
115:3623–3633. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Shimizu J, Yamazaki S and Sakaguchi S:
Induction of tumor immunity by removing
CD25+CD4+ T cells: a common basis between
tumor immunity and autoimmunity. J Immunol. 163:5211–5218.
1999.PubMed/NCBI
|
|
18.
|
Onizuka S, Tawara I, Shimizu J, Sakaguchi
S, Fujita T and Nakayama E: Tumor rejection by in vivo
administration of anti-CD25 (interleukin-2 receptor alpha)
monoclonal antibody. Cancer Res. 59:3128–3133. 1999.PubMed/NCBI
|
|
19.
|
Sun JC, Williams MA and Bevan MJ:
CD4+ T cells are required for the maintenance, not
programming, of memory CD8+ T cells after acute
infection. Nat Immunol. 5:927–933. 2004.
|
|
20.
|
Pardoll DM and Topalian SL: The role of
CD4+ T cell responses in antitumor immunity. Curr Opin
Immunol. 10:588–594. 1998.
|
|
21.
|
Schattner EJ, Mascarenhas J, Bishop J, et
al: CD4+ T-cell induction of Fas-mediated apoptosis in
Burkitt’s lymphoma B cells. Blood. 88:1375–1382. 1996.
|
|
22.
|
Thomas WD and Hersey P: TNF-related
apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas
ligand-resistant melanoma cells and mediates CD4 T cell killing of
target cells. J Immunol. 161:2195–2200. 1998.PubMed/NCBI
|
|
23.
|
Fruh K and Yang Y: Antigen presentation by
MHC class I and its regulation by interferon gamma. Curr Opin
Immunol. 11:76–81. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Zhang Y, Wakita D, Chamoto K, et al: Th1
cell adjuvant therapy combined with tumor vaccination: a novel
strategy for promoting CTL responses while avoiding the
accumulation of Tregs. Int Immunol. 19:151–161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Muranski P and Restifo NP: Adoptive
immunotherapy of cancer using CD4(+) T cells. Curr Opin Immunol.
21:200–208. 2009.
|
|
26.
|
Ting CC, Hargrove ME and Yun YS:
Augmentation by anti-T3 antibody of the lymphokine-activated killer
cell-mediated cytotoxicity. J Immunol. 141:741–748. 1988.PubMed/NCBI
|
|
27.
|
Anderson PM, Blazar BR, Bach FH and Ochoa
AC: Anti-CD3 + IL-2-stimulated murine killer cells. In vitro
generation and in vivo antitumor activity. J Immunol.
142:1383–1394. 1989.
|
|
28.
|
Takayama T, Sekine T, Makuuchi M, et al:
Adoptive immunotherapy to lower postsurgical recurrence rates of
hepatocellular carcinoma: a randomised trial. Lancet. 356:802–807.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Kimura H and Yamaguchi Y: A phase III
randomized study of interleukin-2 lymphokine-activated killer cell
immunotherapy combined with chemotherapy or radiotherapy after
curative or noncurative resection of primary lung carcinoma.
Cancer. 80:42–49. 1997. View Article : Google Scholar
|
|
30.
|
Chang AE and Shu S: Current status of
adoptive immunotherapy of cancer. Crit Rev Oncol Hematol.
22:213–228. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Uno K, Nakano K, Maruo N, et al:
Determination of interferon-alpha-producing capacity in whole blood
cultures from patients with various diseases and from healthy
persons. J Interferon Cytokine Res. 16:911–918. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Uno K, Hirosaki M, Kakimi K, et al:
Impaired IFN-alpha production and the risk of cancer development. J
Interferon Cytokine Res. 27:1013–1017. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Nishimura T, Iwakabe K, Sekimoto M, et al:
Distinct role of antigen-specific T helper type 1 (Th1) and Th2
cells in tumor eradication in vivo. J Exp Med. 190:617–627. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Trinchieri G: Interleukin-12 and the
regulation of innate resistance and adaptive immunity. Nat Rev
Immunol. 3:133–146. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Hung K, Hayashi R, Lafond-Walker A,
Lowenstein C, Pardoll D and Levitsky H: The central role of CD4(+)
T cells in the antitumor immune response. J Exp Med. 188:2357–2368.
1998.
|
|
36.
|
Romagnani S: Human TH1 and TH2 subsets:
doubt no more. Immunol Today. 12:256–257. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Fallarino F, Grohmann U, Bianchi R, Vacca
C, Fioretti MC and Puccetti P: Th1 and Th2 cell clones to a poorly
immunogenic tumor antigen initiate CD8+ T cell-dependent
tumor eradication in vivo. J Immunol. 165:5495–5501. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Nishikawa H, Kato T, Tawara I, et al:
IFN-gamma controls the generation/activation of
CD4+CD25+ regulatory T cells in antitumor
immune response. J Immunol. 175:4433–4440. 2005.PubMed/NCBI
|
